Join
Live feed
·
PRReleasevia Quantisnow
Ultragenyx Pharmaceutical Inc. logo

Ultragenyx Announces Marketing Authorisation Application (MAA) Submission to the European Medicines Agency (EMA) for the First Investigational Gene Therapy for MPS IIIA (Sanfilippo Syndrome Type A)

ByQuantisnow·Wall Street's wire, on your screen.
RARE· Ultragenyx Pharmaceutical Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track RARE (Ultragenyx Pharmaceutical Inc.) and more on Quantisnow.